About FSHD Canada Foundation

Move To A Cure...
A Cure To Move

Funding research to help find a cure for Canadians who suffer from FSHD.

In vivo model to validate drugs targeting DUX4 enhancer/promoter activity

Principle Investigator: Yosuke Hiramuki (at Peter Jone’s laboratory) Research Institution: University of Nevada DUX4 is normally expressed in testis in healthy individuals and aberrantly expressed in specific skeletal muscles of…

Read More

Pre-clinical testing for FSHD CRISPR-inhibition therapy

Principle Investigator: Associate Professor Peter Jones Research Institution: University of Nevada CRISPR technology provides an avenue for targeting and correcting virtually any sequence in the human genome, with long-term or…

Read More

Facio Therapies

Facio Therapies, established in 2014, is a Netherlands-based company with a single focus – to overcome FSHD by developing a causal therapy that restores the natural repression of muscle-toxic DUX4.…

Read More

Srideep Dey

Kitchener, ON

I was diagnosed with fshd at the age of 10, now I'm 23. I also face the same difficulties, among which climbing staircase is the worst, and I am scared…

Read More

Shanon

Spruce Grove, AB

I was a diagnosed at the age of 13 (1983). Neither of my parents have nor carry the gene. There is no family history. When I was 23, I had…

Read More

John Mora

Toronto, ON

Good evening, my name is John. I was diagnosed with FSHD Muscular Dystrophy on January of 2015. Before my diagnosis I used to train MMA and kickboxing, live a normal…

Read More

Our Mission

The singular goal of the FSHD Canada Foundation is to help find a cure — as soon as possible — for Canadians who suffer with FSHD.

To accomplish this the Foundation aims to reach out to all Canadians to make them aware of what is going on in FSHD research and to solicit financial support for the critical research required to find a cure. The Foundation will then use these funds to support FSHD research — in Canada and around the world.

Learn More

What is FSHD?

Facioscapulohumeral muscular dystrophy or FSHD is the most prevalent of the nine primary types of muscular dystrophy affecting adults and children. Muscular dystrophy in general connotes a genetic, hereditary muscle disease that causes progressive muscle weakness. FSHD is also broadly characterized as a neuromuscular disease (NMD), as muscular dystrophy is a subset of NMD. Muscular dystrophies are alike in that they cause progressive skeletal muscle weakness, defects in the biochemical, physical and structural components of muscle, and the death of muscle cells and tissue. However, researchers believe that the causes of each of the muscular dystrophies are not necessarily the same.

Learn More

https://twitter.com/#!/FSHDCanada/ http://www.facebook.com/pages/FSHD-Canada/331378503625267 /contact Suite 201, 1100 1st St. SE Calgary, Alberta T2G 1B1 403.470.0141 neil.camarta@fshd.ca